Glycemic control of type 2 diabetic patients with coronavirus disease during hospitalization: a proposal for early insulin therapy
2020; American Physiological Society; Volume: 318; Issue: 6 Linguagem: Inglês
10.1152/ajpendo.00163.2020
ISSN1522-1555
Autores Tópico(s)Diabetes and associated disorders
ResumoLetter to the EditorGlycemic control of type 2 diabetic patients with coronavirus disease during hospitalization: a proposal for early insulin therapyAfif Nakhleh and Naim ShehadehAfif NakhlehInstitute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, Haifa, Israel and Naim ShehadehInstitute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, Haifa, IsraelPublished Online:13 May 2020https://doi.org/10.1152/ajpendo.00163.2020MoreFiguresReferencesRelatedInformationSectionsDISCLOSURESAUTHOR CONTRIBUTIONSAUTHOR NOTESPDF (71 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookXLinkedInWeChat to the editor: The world is watching the progress of coronavirus disease (COVID‐19) pandemic. Older age and pre-existing medical conditions, specifically diabetes mellitus, hypertension, ischemic heart disease, and chronic lung disease, are associated with a more severe course of COVID-19 (5a). Diabetes mellitus is one of the most prevalent comorbidities among patients hospitalized due to COVID-19 (7). Data obtained from 21 hospitals in Wuhan, China, showed that 25% of the reported COVID-19 fatalities had a history of diabetes mellitus (33). Diabetes and ambient hyperglycemia were independent predictors for death and morbidity in patients with severe acute respiratory syndrome (14, 34). In this letter, we discuss the putative roles of angiotensin-converting enzyme II (ACE2) in glucose homeostasis in patients with type 2 diabetes and COVID-19 and introduce the proposed benefit of early insulin therapy in patients that warrant hospital care. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses angiotensin-converting enzyme II (ACE2) receptor for host cell entry and the serine protease TMPRSS2 for virus spike protein priming (16). The binding of SARS-CoV-1 Spike protein to ACE2 activates disintegrin and metalloprotease-17 (ADAM17) and induces ACE2 shedding via a process tightly coupled with TNF-α production (15). ADAM17-mediated ACE2 shedding facilitates SARS-CoV-1 entry and induces tissue damage by TNF-α production (15). Interestingly, Kuba et al. (22) found that SARS-CoV-1 infection downregulates ACE2 expression in the mice lungs, and this downregulation was associated with the severity of lung injury. Considering that SARS-CoV-1 and SARS-CoV-2 share >70% sequence in the Spike protein (31), SARS‐CoV‐2 infection might also downregulate the ACE2 expression in the same manner and play a role in the pathological process of the lung injury. ADAM17-mediated ACE2 ectodomain shedding might compromise the renin-angiotensin system (RAS) compensatory axis by impairing ACE2 enzymatic activity or its ability to process angiotensin II on the cell surface. Recently, Monteil et al. (23) showed that human recombinant soluble ACE2 significantly blocks SARS-CoV-2 infections, providing a rationale that soluble ACE2 might not only protect from lung injury but also block the SARS-CoV-2 from entering target cells. ACE2 is expressed in several tissues including the kidney and recognized to be renoprotective by degrading angiotensin II to angiotensin(1–7) (9). The ACE2 receptor protects against lung injury by modulating of the RAS and decreasing angiotensin II levels (19). Accumulating evidence supports the protective roles of ACE2 in diabetes. ACE2 is expressed in the pancreas and several insulin-sensitive tissues and might play important roles in glucose homeostasis. First, ACE2 deficiency leads to altered glucose metabolism; ACE2-knockout mice showed a β-cell defect associated with a decrease in insulin secretion in a manner that is not dependent on angiotensin II but may reflect the collectrin-like action of ACE2 (2, 24). In the db/db mouse model (a classic model of type 2 diabetes), ACE2 overexpression in the pancreas significantly improved glucose tolerance, enhanced islet function, and increased β-cell proliferation and insulin content (3). Second, loss of ACE2 increases insulin resistance in high-calorie diet-fed mice, by reduction of GLUT4, and administration of angiotensin(1–7) improved insulin tolerance, suggesting a significant role of angiotensin(1–7) in glucose homeostasis (30). Angiotensin(1–7) improves the action of insulin and opposes the negative effect that angiotensin II exerts at this level (36). Third, ACE2 is thought to act as a compensatory mechanism for hyperglycemia-induced RAS activation. Hyperglycemia increases ADAM17 activity and renal ACE2 shedding into urine in mice (6, 32). This urinary ACE2 excretion correlated positively with the progression of diabetic renal injury represented by progressive albuminuria, mesangial matrix expansion, and renal fibrosis, resembling an unopposed angiotensin II effect. Loss of ACE2 in mice disrupts the balance of the RAS in a diabetic state and leads to an angiotensin II/AT1 receptor-dependent systolic dysfunction and impaired vascular function (26). In humans, urinary ACE2 levels are significantly higher in insulin-resistant patients and type 2 diabetes mellitus than in controls with normal glucose tolerance (25). In addition, urinary ACE2 appears to be positively associated with inflammatory cytokines (25). Based on the aforementioned findings, patients with COVID-19 might be at increased risk of developing hyperglycemia. The proposed mechanism is SARS-CoV-2-mediated downregulation of ACE2 expression, which may hypothetically decrease insulin secretion and increase insulin resistance, accompanied by hyperglycemia-induced RAS activation. Moreover, the localization of ACE2 expression in the endocrine part of the pancreas suggests that SARS-CoV-2 might enter islets using ACE2 as its receptor and damage islets causing acute diabetes. In fact, Yang et al. (35) reported that ~50% of SARS patients who had no previous history of diabetes or steroid treatment, developed clinically significant hyperglycemia during hospitalization, but only 10% had diabetes after 3 yr of follow-up. ADAM17 activation by SARS‐CoV‐2 might also increase the risk of hyperglycemia. In mice, accumulating evidence suggests that increased ADAM17 activity results in increased insulin resistance and hyperglycemia (11). ADAM17 plays a potential role in inflammation, as it can cleave and thereby activate a variety of cytokines and cytokine receptors including tumor necrosis factor α (TNFα) and the interleukin-6 receptor (IL-6R) (10). Accumulating evidence suggests that patients with severe COVID-19 and acute respiratory distress syndrome (ARDS) might have a cytokine storm syndrome, including high levels of IL-6 and TNFα (5). Meanwhile, RAS activation can propagate the acute lung injury (36). Furthermore, increased inflammation might also contribute to the development of islet β-cell failure (8). Hyperglycemia is commonly observed during acute and critical illness (18). Controlling hyperglycemia with insulin is crucial in the management of critically ill patients. Early administration of insulin in acute illness is associated with better outcomes and lower mortality rates (18). Early insulin therapy in patients with type 2 diabetes with COVID-19 disease that warrant hospital care appears to have several advantages. First, insulin exerts immunomodulatory effects independent of glycemic control. Insulin inhibits synthesis of proinflammatory factors, including TNFα and IL-6, and might have a protective role in ARDS (17). Second, studies in mouse models suggest that management of hyperglycemia restores ACE2 and ADAM17 expression and the RAS balance. In the Akita mouse model of type 1 diabetes, insulin treatment normalized hyperglycemia, decreased urinary ACE2 excretion, restored renal ACE2 and ADAM17 expression to physiological levels, and normalized the rate of shedding (29). Furthermore, insulin significantly increased ACE2/ACE activity ratio in the nonobese diabetic (NOD) mice lung and restored ACE and ACE2 and ACE2/ACE ratio activities in serum samples (27). Thus, it can be hypothesized that insulin therapy might be protective against SARS-CoV-2-induced lung injury by restoring ACE2 expression to physiological levels on the cell surface and decreasing angiotensin II levels (19). Third, early insulin therapy reduces the risk of developing diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar states in acutely ill patients. In fact, a recent case report suggests a potential for β-cell damage caused by the SARS-CoV-2, leading to insulin deficiency and DKA (20). Other antihyperglycemic medications might have a protective role in ARDS. Metformin, peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors attenuated lung injury in murine models (13, 21, 38, 39). Some of these medications might modulate ACE2 expression. Pioglitazone increases ACE2 protein expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis (37). However, in type 2 diabetic mice, rosiglitazone normalized hyperglycemia, attenuated renal injury, and decreased urinary ACE2 excretion and renal ADAM17 protein expression but, unlike insulin, did not affect renal ACE2 expression (6). Noteworthy, liraglutide, a GLP-1 agonist, upregulated ACE2 expression in the lungs of both diabetic and control rats (28). Thus, liraglutide might theoretically exert protective effects against SARS-CoV-2 induced lung injury. Some glucose-lowering agents lack safety data concerning their use in patients with moderate or severe COVID-19 pneumonia. Lactic acidosis associated with metformin, or diabetic ketoacidosis associated with sodium glucose cotransporter 2 (SGLT-2) inhibitors are rare events; however, recently published treatment recommendations advise these drugs should be discontinued for patients with severe symptoms of COVID-19 to reduce the risk of acute metabolic decompensation (4). No convincing evidence exists to suggest that incretin-based therapies should be discontinued; however, more prospective studies comparing these agents with insulin are required to establish their efficacy and safety in hospitalized patients. Given the wide clinical spectrum of COVID-19 and the fact that patients needing hospital care may deteriorate rapidly, an early introduction of insulin in type 2 diabetic patients with COVID-19 is to be encouraged upon admission to the hospital. The target glucose range is 140–180 mg/dL (7.8–10.0 mmol/L) in most cases (1). Beyond controlling hyperglycemia, early administration of insulin is hypothesized to exert positive immunomodulatory effects, modulate RAS, and protect against lung injury. Future studies should be carried out to elucidate the interface between diabetes and COVID-19.DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONS A.N. drafted manuscript; A.N. and N.S. edited and revised manuscript; A.N. and N.S. approved final version of manuscript.AUTHOR NOTESCorrespondence: A. Nakhleh (anakhleh@gmail.com). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes. Diabetes Care 43, Suppl 1: S193–S202, 2020. doi:10.2337/dc20-S015. Crossref | PubMed | Web of Science | Google Scholar2. Bernardi S, Tikellis C, Candido R, Tsorotes D, Pickering RJ, Bossi F, Carretta R, Fabris B, Cooper ME, Thomas MC. ACE2 deficiency shifts energy metabolism towards glucose utilization. Metabolism 64: 406–415, 2015. doi:10.1016/j.metabol.2014.11.004. Crossref | PubMed | Web of Science | Google Scholar3. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59: 2540–2548, 2010. doi:10.2337/db09-0782. Crossref | PubMed | Web of Science | Google Scholar4. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L, Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. In press. doi:10.1016/S2213-8587(20)30152-2. Crossref | PubMed | Web of Science | Google Scholar5. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 20: 269–270, 2020. doi:10.1038/s41577-020-0308-3. Crossref | PubMed | Web of Science | Google Scholar5a. Centre for Evidence-Based Medicine. Global Covid-19 Case Fatality Rates (Online). https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/ [6 May 2020].Google Scholar6. Chodavarapu H, Grobe N, Somineni HK, Salem ESB, Madhu M, Elased KM. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 8: e62833, 2013. doi:10.1371/journal.pone.0062833. Crossref | PubMed | Web of Science | Google Scholar7. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Dunning J, Openshaw PJM, Baillie JK, Semple MG. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol (Preprint). medRxiv Apr 28: 2020.04.23.20076042. doi:10.1101/2020.04.23.20076042.Crossref | Google Scholar8. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J Mol Med (Berl) 81: 455–470, 2003. doi:10.1007/s00109-003-0450-y. Crossref | PubMed | Web of Science | Google Scholar9. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1–E9, 2000. doi:10.1161/01.RES.87.5.e1. Crossref | PubMed | Web of Science | Google Scholar10. Düsterhöft S, Lokau J, Garbers C. The metalloprotease ADAM17 in inflammation and cancer. Pathol Res Pract 215: 152410, 2019. doi:10.1016/j.prp.2019.04.002. Crossref | PubMed | Web of Science | Google Scholar11. Fiorentino L, Vivanti A, Cavalera M, Marzano V, Ronci M, Fabrizi M, Menini S, Pugliese G, Menghini R, Khokha R, Lauro R, Urbani A, Federici M. Increased tumor necrosis factor α-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 51: 103–110, 2010. doi:10.1002/hep.23250. Crossref | PubMed | Web of Science | Google Scholar13. Grommes J, Mörgelin M, Soehnlein O. Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment. Eur Respir J 40: 416–423, 2012. doi:10.1183/09031936.00091011. Crossref | PubMed | Web of Science | Google Scholar14. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. In press. doi:10.1002/dmrr.3319. Crossref | PubMed | Web of Science | Google Scholar15. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci USA 105: 7809–7814, 2008. doi:10.1073/pnas.0711241105. Crossref | PubMed | Web of Science | Google Scholar16. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271–280, 2020. doi:10.1016/j.cell.2020.02.052. Crossref | PubMed | Web of Science | Google Scholar17. Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit Care Med 37: 2455–2464, 2009. doi:10.1097/CCM.0b013e3181a0fea5. Crossref | PubMed | Web of Science | Google Scholar18. Honiden S, Schultz A, Im SA, Nierman DM, Gong MN. Early versus late intravenous insulin administration in critically ill patients. Intensive Care Med 34: 881–887, 2008. doi:10.1007/s00134-007-0978-3. Crossref | PubMed | Web of Science | Google Scholar19. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436: 112–116, 2005. doi:10.1038/nature03712. Crossref | PubMed | Web of Science | Google Scholar20. Jie Chee Y, Jia Huey Ng S, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. In press. doi:10.1016/j.diabres.2020.108166. Crossref | PubMed | Web of Science | Google Scholar21. Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 315: L834–L845, 2018. doi:10.1152/ajplung.00031.2018. Link | Web of Science | Google Scholar22. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11: 875–879, 2005. doi:10.1038/nm1267. Crossref | PubMed | Web of Science | Google Scholar23. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. In press. doi:10.1016/j.cell.2020.04.004. Crossref | PubMed | Web of Science | Google Scholar24. Niu MJ, Yang JK, Lin SS, Ji XJ, Guo LM. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 34: 56–61, 2008. doi:10.1007/s12020-008-9110-x. Crossref | PubMed | Web of Science | Google Scholar25. Park SE, Kim WJ, Park SW, Park JW, Lee N, Park CY, Youn BS. High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. Eur J Endocrinol 168: 203–210, 2013. doi:10.1530/EJE-12-0782. Crossref | PubMed | Web of Science | Google Scholar26. Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, Lo J, Grant MB, Zhong J, Kassiri Z, Oudit GY. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 110: 1322–1335, 2012. doi:10.1161/CIRCRESAHA.112.268029. Crossref | PubMed | Web of Science | Google Scholar27. Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 18: E563, 2017. doi:10.3390/ijms18030563. Crossref | PubMed | Web of Science | Google Scholar28. Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM, Santisteban P, González-Matías LC, Vigo E, Mallo F. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology 156: 3559–3569, 2015. doi:10.1210/en.2014-1685. Crossref | PubMed | Web of Science | Google Scholar29. Salem ESB, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol 306: F629–F639, 2014. doi:10.1152/ajprenal.00516.2013. Link | Web of Science | Google Scholar30. Takeda M, Yamamoto K, Takemura Y, Takeshita H, Hongyo K, Kawai T, Hanasaki-Yamamoto H, Oguro R, Takami Y, Tatara Y, Takeya Y, Sugimoto K, Kamide K, Ohishi M, Rakugi H. Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes 62: 223–233, 2013. doi:10.2337/db12-0177. Crossref | PubMed | Web of Science | Google Scholar31. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q, Zhou H, Yan J, Qi J. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. In press. doi:10.1016/j.cell.2020.03.045. Crossref | PubMed | Web of Science | Google Scholar32. Xiao F, Zimpelmann J, Agaybi S, Gurley SB, Puente L, Burns KD. Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. PLoS One 9: e85958, 2014. doi:10.1371/journal.pone.0085958. Crossref | PubMed | Web of Science | Google Scholar33. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open 3: e205619, 2020. doi:10.1001/jamanetworkopen.2020.5619. Crossref | PubMed | Web of Science | Google Scholar34. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, Sun GZ, Yang GR, Zhang XL, Wang L, Xu X, Xu XP, Chan JC. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 23: 623–628, 2006. doi:10.1111/j.1464-5491.2006.01861.x. Crossref | PubMed | Web of Science | Google Scholar35. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 47: 193–199, 2010. doi:10.1007/s00592-009-0109-4. Crossref | PubMed | Web of Science | Google Scholar36. Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care 21: 305, 2017. doi:10.1186/s13054-017-1882-z. Crossref | PubMed | Web of Science | Google Scholar37. Zhang W, Xu Y-Z, Liu B, Wu R, Yang Y-Y, Xiao X-Q, Zhang X. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. Sci World J 2014: 603409, 2014. doi:10.1155/2014/603409. Crossref | PubMed | Web of Science | Google Scholar38. Zhu T, Li C, Zhang X, Ye C, Tang S, Zhang W, Sun J, Huang N, Wen F, Wang D, Deng H, He J, Qi D, Deng W, Yang T. GLP-1 analogue liraglutide enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway. Mediators Inflamm 2018: 3601454, 2018. doi:10.1155/2018/3601454. Crossref | PubMed | Web of Science | Google Scholar39. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, Siegal GP, Abraham E. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 178: 168–179, 2008. doi:10.1164/rccm.200710-1602OC. Crossref | PubMed | Web of Science | Google Scholar CollectionsAPS Cross-Journal CollectionsCoronavirus-Related Papers Cited ByCrosstalk between SARS-CoV-2 Infection and Type II Diabetes1 Dec 2022 | Combinatorial Chemistry & High Throughput Screening, Vol. 25, No. 14Commentary: A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. A Metabolic Endocrinology Perspective28 April 2022 | Frontiers in Endocrinology, Vol. 13Pediatric diabetic ketoacidosis as type 1 diabetes debut with concurrent SARS-CoV-2 infection: A case report13 May 2022 | SAGE Open Medical Case Reports, Vol. 10Diabetic Ketoacidosis in Patients With COVID-191 May 2021 | The American Journal of the Medical Sciences, Vol. 361, No. 5Cardiometabolic vigilance in COVID-19 and resource husbandry in resource-challenged times: Clinical practice- based expert opinion1 Jan 2021 | Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Vol. 15, No. 1Lifestyle and severe SARS-CoV-2 infections: Does the individual metabolic burden determines the outcome?10 October 2020 | Journal of the Renin-Angiotensin-Aldosterone System, Vol. 21, No. 4Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle17 September 2020 | Frontiers in Endocrinology, Vol. 11 More from this issue > Volume 318Issue 6June 2020Pages E835-E837 Copyright & PermissionsCopyright © 2020 the American Physiological Societyhttps://doi.org/10.1152/ajpendo.00163.2020PubMed32401039History Received 20 April 2020 Accepted 30 April 2020 Published online 13 May 2020 Published in print 1 June 2020 Metrics See more details Posted by 8 X users Referenced in 1 patents 114 readers on Mendeley 11 CITATIONS 11 Total citations 1 Recent citation n/a Field Citation Ratio 0.51 Relative Citation Ratio publications11supporting0mentioning12contrasting0Smart Citations110120Citing PublicationsSupportingMentioningContrastingView CitationsSee how this article has been cited at scite.aiscite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made. See more details Posted by 8 X users Referenced in 1 patents 114 readers on Mendeley We recommendRelated molecular mechanisms of COVID-19, hypertension, and diabetesErman Akkus, American Journal of Physiology - Endocrinology and Metabolism, 2020SARS-CoV-2 perturbs the Renin-Angiotensin System and energy metabolismJun Mori, American Journal of Physiology - Endocrinology and Metabolism, 2020COVID-19 pandemic, coronaviruses, and diabetes mellitusRanganath Muniyappa, American Journal of Physiology - Endocrinology and Metabolism, 2020Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused miceKavaljit H. Chhabra, American Journal of Physiology - Endocrinology and Metabolism, 2013Role of angiotensin converting enzyme 2 and pericytes in cardiac complications of COVID-19 infectionFulton A. Robinson, American Journal of Physiology - Heart and Circulatory Physiology, 2020Powered by Privacy policyGoogle Analytics settings
Referência(s)